Adocia

Adocia is a clinical-stage biotechnology company headquartered in Lyon, France, dedicated to the research and development of innovative formulations for therapeutic proteins and peptides. Founded in 2005 by Gérard, Olivier, and Rémi Soula, the company leverages its expertise in polymer science to address significant unmet medical needs in the treatment of metabolic diseases, including diabetes and obesity. By focusing on enhancing the effectiveness, safety, and convenience of existing treatments, Adocia aims to improve patient outcomes and quality of life globally.

Adocia’s mission is to deliver 'Innovative medicines for everyone, everywhere,' by providing more effective, accessible, and user-friendly treatments for metabolic disorders.

• Developed a robust portfolio of proprietary technology platforms including BioChaperone® and AdoXLong™.
• Holds over 25 patent families protecting its core formulation technologies.
• Successfully reported positive Phase 3 trial results for BioChaperone® Lispro in collaboration with Tonghua Dongbao.
• Maintains a strategic business model focused on clinical proof-of-concept and high-value licensing partnerships.

Sources

• Official Adocia Website
• Euronext Paris Listing